Identification
- Summary
Desonide is a topical corticosteroid used for the symptomatic treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
- Brand Names
- Desonate, Desowen, Desrx, Lokara, Tridesilon, Verdeso
- Generic Name
- Desonide
- DrugBank Accession Number
- DB01260
- Background
A nonfluorinated corticosteroid anti-inflammatory agent used topically for dermatoses.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Desonide (DB01260)
- Weight
- Average: 416.5073
Monoisotopic: 416.219888756 - Chemical Formula
- C24H32O6
- Synonyms
- 11β,21-dihydroxy-16α,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione
- 11β,21-dihydroxy-16α,17-isopropylidenedioxypregna-1,4-diene-3,20-dione
- 11β,21-dihydroxy-16α,17α-isopropylidenedioxypregna-1,4-diene-3,20-dione
- 16α-hydroxyprednisole-16,17-acetonide
- 16α-hydroxyprednisolone-16α,17-acetonide
- 16α,17α-isopropylidenedioxyprednisolone
- Desfluorotriamcinolone acetonide
- Desonida
- Desonide
- Desonidum
- External IDs
- D-2083
- D2083
Pharmacology
- Indication
For the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatose.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Desonide is a synthetic nonfluorinated corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents.
- Mechanism of action
Like other topical corticosteroids, desonide has anti-inflammatory, antipruritic and vasoconstrictive properties. The drug binds to cytosolic glucocorticoid receptors. This complex migrates to the nucleus and binds to genetic elements on the DNA. This activates and represses various genes. However corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.
Target Actions Organism AGlucocorticoid receptor agonistHumans - Absorption
Topical corticosteroids can be absorbed from normal intact skin, inflammation and/or other disease processes in the skin may increase percutaneous absorption.
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbametapir The serum concentration of Desonide can be increased when it is combined with Abametapir. Acarbose The risk or severity of hyperglycemia can be increased when Desonide is combined with Acarbose. Acetohexamide The risk or severity of hyperglycemia can be increased when Desonide is combined with Acetohexamide. Acetyldigitoxin The risk or severity of adverse effects can be increased when Desonide is combined with Acetyldigitoxin. Albiglutide The risk or severity of hyperglycemia can be increased when Desonide is combined with Albiglutide. Allogeneic processed thymus tissue The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Desonide. Alogliptin The risk or severity of hyperglycemia can be increased when Desonide is combined with Alogliptin. Aminoglutethimide The therapeutic efficacy of Desonide can be decreased when used in combination with Aminoglutethimide. Apalutamide The serum concentration of Desonide can be decreased when it is combined with Apalutamide. Avanafil The serum concentration of Avanafil can be increased when it is combined with Desonide. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- International/Other Brands
- Desocort (Galderma) / Tridesilon (Bayer)
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Desocort Cream 0.05% Cream .05 % Topical Galderma 1994-12-31 2007-08-02 Canada 
Desocort Lotion - 0.05% Lotion .05 % Topical Galderma 1994-12-31 2016-08-04 Canada Desocort Ointment - 0.05% Ointment .05 % Topical Galderma 1994-12-31 2016-08-04 Canada Desonate Gel 0.5 mg/1g Topical Intendis Inc. 2010-01-28 Not applicable US 
Desonate Gel 0.5 mg/1g Topical Bayer HealthCare Pharmaceuticals Inc. 2006-10-20 Not applicable US Desonate Gel 0.5 mg/1g Topical SkinMedica 2007-03-30 Not applicable US Desonate Gel 0.5 mg/1g Topical LEO Pharma Inc. 2018-10-01 Not applicable US Desonide Cream 0.5 mg/1g Topical Padagis Israel Pharmaceuticals Ltd 2006-04-11 2023-08-31 US Desonide Ointment 0.5 mg/1g Topical Physicians Total Care, Inc. 2006-06-21 Not applicable US Desonide Ointment 0.5 mg/1g Topical Padagis Israel Pharmaceuticals Ltd 2006-08-22 Not applicable US - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Desonide Ointment 0.5 mg/1g Topical Taro Pharmaceuticals U.S.A., Inc. 1994-08-03 Not applicable US Desonide Cream 0.5 mg/1g Topical Tiber Laboratories, LLC 1992-06-30 2012-06-30 US Desonide Gel 0.5 mg/1g Topical Cintex Services, Llc 2020-07-09 Not applicable US Desonide Cream 0.5 mg/1g Topical Actavis Pharma, Inc. 2013-08-01 Not applicable US Desonide Cream 0.5 mg/1g Topical Zydus Lifesciences Limited 2019-11-25 Not applicable US Desonide Cream 0.5 mg/1g Topical bryant ranch prepack 2020-06-17 Not applicable US Desonide Ointment 0.5 mg/1g Topical North Star Rx Llc 2017-09-15 Not applicable US Desonide Lotion 0.5 mg/1mL Topical Aleor Dermaceuticals Limited 2020-08-31 Not applicable US Desonide Cream 0.5 mg/1g Topical Alembic Pharmaceuticals, Inc. 2022-12-08 Not applicable US Desonide Cream 0.5 mg/1g Topical Glenmark Pharmaceuticals Inc., USA 2017-07-24 2023-07-01 US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image PRECORT-A KREM Desonide (0.125 %) + Clioquinol (3 %) Cream Topical KOÇAK FARMA İLAÇ VE KİMYA SAN. A.Ş. 2020-08-14 Not applicable Turkey 
PRECORT-A POMAD Desonide (0.125 %) + Clioquinol (3 %) Ointment Topical KOÇAK FARMA İLAÇ VE KİMYA SAN. A.Ş. 2020-08-14 Not applicable Turkey PREDNOL-A 30 GR KREM Desonide (0.125 %) + Clioquinol (3 %) Cream Topical GENSENTA İLAÇ SANAYİ VE TİCARET A.Ş. 2020-08-14 Not applicable Turkey PREDNOL-A 30 GR POMAD Desonide (0.125 %) + Clioquinol (3 %) Ointment Topical GENSENTA İLAÇ SANAYİ VE TİCARET A.Ş. 2020-08-14 Not applicable Turkey
Categories
- ATC Codes
- S01BA11 — Desonide
- S01BA — Corticosteroids, plain
- S01B — ANTIINFLAMMATORY AGENTS
- S01 — OPHTHALMOLOGICALS
- S — SENSORY ORGANS
- D07BB — Corticosteroids, moderately potent, combinations with antiseptics
- D07B — CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS
- D07 — CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
- D — DERMATOLOGICALS
- Drug Categories
- Adrenal Cortex Hormones
- Anti-Inflammatory Agents
- Corticosteroid Hormone Receptor Agonists
- Corticosteroids
- Corticosteroids, Moderately Potent (Group II)
- Cytochrome P-450 CYP3A Inducers
- Cytochrome P-450 CYP3A Substrates
- Cytochrome P-450 CYP3A4 Inducers
- Cytochrome P-450 CYP3A4 Inducers (strength unknown)
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 Substrates
- Dermatologicals
- Fused-Ring Compounds
- Immunosuppressive Agents
- Ophthalmologicals
- Pregnadienes
- Pregnadienetriols
- Pregnanes
- Sensory Organs
- Steroids
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Steroids and steroid derivatives
- Sub Class
- Hydroxysteroids
- Direct Parent
- 21-hydroxysteroids
- Alternative Parents
- Gluco/mineralocorticoids, progestogins and derivatives / 20-oxosteroids / 3-oxo delta-1,4-steroids / 11-beta-hydroxysteroids / Delta-1,4-steroids / Ketals / Alpha-hydroxy ketones / 1,3-dioxolanes / Secondary alcohols / Cyclic ketones show 5 more
- Substituents
- 11-beta-hydroxysteroid / 11-hydroxysteroid / 20-oxosteroid / 21-hydroxysteroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid / Acetal / Alcohol / Aliphatic heteropolycyclic compound / Alpha-hydroxy ketone show 18 more
- Molecular Framework
- Aliphatic heteropolycyclic compounds
- External Descriptors
- 11beta-hydroxy steroid, cyclic ketal, 20-oxo steroid, 3-oxo-Delta(1),Delta(4)-steroid, corticosteroid, 21-hydroxy steroid (CHEBI:204734)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- J280872D1O
- CAS number
- 638-94-8
- InChI Key
- WBGKWQHBNHJJPZ-LECWWXJVSA-N
- InChI
- InChI=1S/C24H32O6/c1-21(2)29-19-10-16-15-6-5-13-9-14(26)7-8-22(13,3)20(15)17(27)11-23(16,4)24(19,30-21)18(28)12-25/h7-9,15-17,19-20,25,27H,5-6,10-12H2,1-4H3/t15-,16-,17-,19+,20+,22-,23-,24+/m0/s1
- IUPAC Name
- (1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.0^{2,9}.0^{4,8}.0^{13,18}]icosa-14,17-dien-16-one
- SMILES
- [H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
References
- Synthesis Reference
Bernstein, S. and Allen, G.R., Jr.; U.S. Patent 2,990,401; June 27, 1961; assigned to American Cyanamid Company. Diassi, P.A. and Principe, P.A.; U.S.Patent 3,549,498; December 22, 1970; assigned to E.R. Squibb & Sons, inc.
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0015389
- KEGG Drug
- D03696
- PubChem Compound
- 5311066
- PubChem Substance
- 46506186
- ChemSpider
- 4470603
- 3254
- ChEBI
- 204734
- ChEMBL
- CHEMBL1201109
- ZINC
- ZINC000004212851
- Therapeutic Targets Database
- DAP001188
- PharmGKB
- PA164776996
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Desonide
- MSDS
- Download (73.7 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Atopic Dermatitis 3 4 Completed Treatment Hyperpigmentation 1 4 Withdrawn Treatment Psoriasis (PsO) 1 3 Completed Treatment Atopic Dermatitis 2 3 Unknown Status Treatment Atopic Dermatitis 1 1 Completed Treatment Vasoconstriction 1 1 Recruiting Basic Science Healthy Subjects (HS) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Actavis Group
- Ameri-Pac Inc.
- Contract Pharm
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- DPT Laboratories Ltd.
- E. Fougera and Co.
- Galderma Laboratories
- Intendis Inc.
- Ivax Pharmaceuticals
- Major Pharmaceuticals
- Medisca Inc.
- Nycomed Inc.
- Palmetto Pharmaceuticals Inc.
- Perrigo Co.
- Pharmedix
- Physicians Total Care Inc.
- Stiefel Labs
- Taro Pharmaceuticals USA
- Dosage Forms
Form Route Strength Cream Topical Cream Topical 0.1 g Emulsion Topical 0.05 g Cream Topical 100 mg Lotion Topical .05 % Cream Topical 0.05 % Ointment Solution Topical Cream Gel Topical 0.5 mg/1g Cream Topical 0.05 g Lotion Topical 0.1 g Cream Topical 3 g Cream Topical .5 mg/1g Lotion Topical .5 mg/1g Lotion Topical 0.5 mg/1g Ointment Topical 0.5 mg/1g Ointment Topical 0.5 mg/01g Solution Topical Cream Topical 0.5 mg/1g Lotion Topical 0.05 % Ointment Topical 0.05 % Lotion Topical Lotion Topical 0.5 mg/1mL Cream Topical Cream Topical 0.05 % w/w Ointment Topical 0.05 % w/w Ointment Topical 0.125 % Cream Topical 0125 % Ointment Topical Ointment Ophthalmic 0.25 % Ointment Ophthalmic 5 G Solution / drops Ophthalmic 0.25 % Solution / drops Ophthalmic 10 ml Lotion Topical Cream Topical 0.05 G/100G Ointment 0.05 G/100G Solution Topical 0.05 G/100G Cream Topical .05 % Ointment Topical .05 % Cream Topical 0.03 g/60g Cream Topical .5 mg / g Ointment Topical .5 mg / g Aerosol, foam Topical 0.05 % Aerosol, foam Topical 0.5 mg/1g - Prices
Unit description Cost Unit DesOwen Lot w/Cetaphil Cream 0.05% Kit Box 255.84USD box Desowen 0.05% ointment kit 217.2USD kit Desowen 0.05% cream kit 212.4USD kit DesOwen 0.05% Lotion 118ml Bottle 183.17USD bottle Desonide powder 152.39USD g DesOwen 0.05% Lotion 59ml Bottle 123.38USD bottle Desonide 0.05% Lotion 118ml Bottle 76.75USD bottle Desonide 0.05% Lotion 59ml Bottle 50.86USD bottle Desonide 0.05% Ointment 60 gm Tube 41.76USD tube Desonide 0.05% Cream 60 gm Tube 41.48USD tube Desonide 0.05% Ointment 15 gm Tube 16.09USD tube Desonide 0.05% Cream 15 gm Tube 16.07USD tube Desowen 0.05% cream 2.43USD g Desonide 0.05% cream 0.81USD g Desocort 0.05 % Ointment 0.32USD g Pms-Desonide 0.05 % Cream 0.28USD g Pms-Desonide 0.05 % Ointment 0.28USD g Desocort 0.05 % Lotion 0.16USD g DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US8460641 No 2013-06-11 2028-11-05 US US8962000 No 2015-02-24 2025-08-31 US US6730288 No 2004-05-04 2019-09-08 US US7029659 No 2006-04-18 2019-09-08 US US6387383 No 2002-05-14 2020-08-03 US US9492384 No 2016-11-15 2025-08-31 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 257-260 Bernstein, S. and Allen, G.R., Jr.; U.S. Patent 2,990,401; June 27, 1961; assigned to American Cyanamid Company. Diassi, P.A. and Principe, P.A.; U.S.Patent 3,549,498; December 22, 1970; assigned to E.R. Squibb & Sons, inc. water solubility Practically insoluble Not Available logP 1.4 Not Available - Predicted Properties
Property Value Source Water Solubility 0.0594 mg/mL ALOGPS logP 2.31 ALOGPS logP 1.9 Chemaxon logS -3.8 ALOGPS pKa (Strongest Acidic) 13.75 Chemaxon pKa (Strongest Basic) -2.9 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 93.06 Å2 Chemaxon Rotatable Bond Count 2 Chemaxon Refractivity 112.06 m3·mol-1 Chemaxon Polarizability 44.59 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9764 Blood Brain Barrier + 0.9382 Caco-2 permeable - 0.6162 P-glycoprotein substrate Substrate 0.7998 P-glycoprotein inhibitor I Non-inhibitor 0.5837 P-glycoprotein inhibitor II Inhibitor 0.6045 Renal organic cation transporter Non-inhibitor 0.7573 CYP450 2C9 substrate Non-substrate 0.8268 CYP450 2D6 substrate Non-substrate 0.9078 CYP450 3A4 substrate Substrate 0.7545 CYP450 1A2 substrate Non-inhibitor 0.909 CYP450 2C9 inhibitor Non-inhibitor 0.8729 CYP450 2D6 inhibitor Non-inhibitor 0.9544 CYP450 2C19 inhibitor Non-inhibitor 0.9521 CYP450 3A4 inhibitor Non-inhibitor 0.536 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9129 Ames test Non AMES toxic 0.8938 Carcinogenicity Non-carcinogens 0.949 Biodegradation Not ready biodegradable 0.9766 Rat acute toxicity 2.5316 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9573 hERG inhibition (predictor II) Non-inhibitor 0.67
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Zinc ion binding
- Specific Function
- Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
- Gene Name
- NR3C1
- Uniprot ID
- P04150
- Uniprot Name
- Glucocorticoid receptor
- Molecular Weight
- 85658.57 Da
References
- Russell GM, Henley DE, Leendertz J, Douthwaite JA, Wood SA, Stevens A, Woltersdorf WW, Peeters BW, Ruigt GS, White A, Veldhuis JD, Lightman SL: Rapid glucocorticoid receptor-mediated inhibition of hypothalamic-pituitary-adrenal ultradian activity in healthy males. J Neurosci. 2010 Apr 28;30(17):6106-15. doi: 10.1523/JNEUROSCI.5332-09.2010. [Article]
- Shaw JR, Gabor K, Hand E, Lankowski A, Durant L, Thibodeau R, Stanton CR, Barnaby R, Coutermarsh B, Karlson KH, Sato JD, Hamilton JW, Stanton BA: Role of glucocorticoid receptor in acclimation of killifish (Fundulus heteroclitus) to seawater and effects of arsenic. Am J Physiol Regul Integr Comp Physiol. 2007 Feb;292(2):R1052-60. Epub 2006 Oct 12. [Article]
- Otte C, Wust S, Zhao S, Pawlikowska L, Kwok PY, Whooley MA: Glucocorticoid receptor gene, low-grade inflammation, and heart failure: the Heart and Soul study. J Clin Endocrinol Metab. 2010 Jun;95(6):2885-91. doi: 10.1210/jc.2009-2251. Epub 2010 Apr 6. [Article]
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- SubstrateInducer
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
Drug created at May 16, 2007 17:31 / Updated at June 02, 2023 16:39